Clinical Trial Update: Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance [NA]

View source ↗

Summary

This completed clinical trial from Nantes University Hospital investigated the roles of PCSK9 and FXR in dyslipidemia associated with obesity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Snippet

Sponsor: Nantes University Hospital | Conditions: Obesity | NA | Status: COMPLETED